Efavirenz + lamivudine + tenofovir

Essential medicine status

General description

A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.

INN	Efavirenz + lamivudine + tenofovir
ATC codes	J05AR11
Medicine type	Chemical agent
EML status history	First added in 2017 (TRS 1006) for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Changed in 2021 (TRS 1035) for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Therapeutic equivalent for	efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Wikipedia	Efavirenz + lamivudine + tenofovir
DrugBank	Efavirenz, Lamivudine, Tenofovir disoproxil

Recommendations

Section Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified